Emerging RTP Biopharmaceutical Companys Research Shows Promising Results for a New Drug Candidate for Asthma, Sepsis, and for Treatment Following a Bioterrorist Attack using Plague.
Raleigh, N.C., Don Wilson, the CEO of Endacea, Inc., an emerging RTP biopharmaceutical company engaged in developing proprietary adenosine receptor antagonists as drugs for asthma, sepsis, and biodefense, will lead part of the discussion at the November 6, 2008, RTP Tech Event at Goodnights.
Sign up for the event at http://newtech.meetup.com/115/
.
0 Responses
Stay in touch with the conversation, subscribe to the RSS feed for comments on this post.
You must be logged in to post a comment.